Pharming Group N.V. today announced its participation in the Oppenheimer Movers in Rare Disease Summit on December 11, 2025 in New York City. This invitation-only event brings together innovative companies and investors focused on rare diseases.

Pharming Group N.V. presents its preliminary (unaudited) financial report for the three months ended September 30, 2025.

Pharming Group N.V. announces that Pharming management will participate in the Jefferies Global Healthcare Conference in London, UK, on November 17-20, 2025.

Pharming Group N.V. confirms that it will report its preliminary (unaudited) financial results for the third quarter 2025 and provide a business update on Thursday, November 6, 2025.

Pharming Group N.V. today announced that 12 abstracts have been accepted for presentation at the American College of Allergy, Asthma & Immunology (ACAAI) 2025 Annual Scientific Meeting taking place in Orlando, Florida on November 6-10.

Pharming Group today announced the implementation of an organizational restructuring to accelerate the Company’s growth.

Pharming Group N.V. today announced that it has been promoted from the Euronext AScX® (Small Cap) to the AMX® (MidCap) index, effective from September 22, 2025.

Pharming Group N.V. announces that Pharming management will participate in the H.C. Wainwright 27th Annual Global Investment Conference in New York on September 8-10, 2025.

Pharming Group N.V. today announced the appointment of Kenneth Lynard as Chief Financial Officer (CFO), effective October 1, 2025.